Part of: The Anatomy of an FDA Warning Letter
TL;DR
- Six FDA centers issue Warning Letters, and which one issues a given letter is determined by product jurisdiction, not by company size, violation severity, or geography.
- CDER (drugs), CDRH (devices), CBER (biologics, including cell and gene therapy), the Human Foods Program (successor to much of CFSAN's enforcement role, covering food and dietary supplements), CTP (tobacco and vape), and CVM (animal health and veterinary drugs) each run against a different statutory and regulatory base.
- A single company making both a drug and a companion diagnostic device can receive Warning Letters from two different centers, on two different tracks, with two different response clocks running simultaneously.
- The numbering format on a letter's identification block (MARCS-CMS, WL-prefixed, or plain CMS#) does not reliably indicate which center issued it — the center is stated separately in the letter body.
Why center jurisdiction is the organizing fact, not an afterthought
It's tempting to read "FDA Warning Letter" as describing one consistent kind of document issued by one consistent kind of process. It doesn't. FDA's Warning Letter authority is distributed across six centers, each grounded in different parts of the Federal Food, Drug, and Cosmetic Act (or, for tobacco, the separate Family Smoking Prevention and Tobacco Control Act) and each applying different implementing regulations. The document format looks similar across centers — identification block, inspection reference, citation section, response demand — but the legal and technical substance underneath that shared format differs meaningfully by center.
The six centers and what each one covers
CDER (Center for Drug Evaluation and Research) issues the highest volume of Warning Letters of any center, covering drug manufacturing and, in adjacent cases, pharmacovigilance and safety-reporting obligations for approved drugs. CDER's citations most often trace to 21 CFR Parts 210 and 211 (CGMP for drugs).
CDRH (Center for Devices and Radiological Health) issues device Warning Letters, now citing against the Quality Management System Regulation (QMSR) under 21 CFR Part 820, effective February 2, 2026 — a framework that replaced most of the prior Quality System Regulation with no transition grace period for open findings (Argus HQ, "Is FDA's new device quality rule a compliance reset?").
CBER (Center for Biologics Evaluation and Research) issues biologics letters, including cell and gene therapy manufacturing citations. A June 2026 CBER letter to Genzyme Ireland Limited, a Sanofi subsidiary, illustrates this track: a quality control unit that failed to enforce CGMP, and lab records showing certain tests repeated up to 11 times without documented justification (Argus HQ, "Genzyme Ireland Limited FDA Warning Letter CBER 26-728681").
The Human Foods Program, the successor to much of the Center for Food Safety and Applied Nutrition's (CFSAN) enforcement role, issues food and dietary supplement letters. Its citations frequently trace to the Foreign Supplier Verification Program (FSVP) under 21 CFR Part 1, Subpart L for imported ingredients, and to the "unapproved new drug" trapdoor for supplements making disease-treatment claims.
CTP (Center for Tobacco Products) issues tobacco and vape letters under the Tobacco Control Act rather than the FD&C Act provisions that drive the other five centers — a genuinely separate statutory basis, not just a separate product category (see the companion spoke on tobacco enforcement for the full distinction).
CVM (Center for Veterinary Medicine) issues animal-health and veterinary drug letters, a smaller-volume but structurally separate track from every other center on this list.
The multi-center company problem
Center jurisdiction attaches to the product, not to the company as a whole. A company that manufactures both a drug and a companion diagnostic device — a common structure in modern pharmaceutical development — can receive Warning Letters from two different centers on two entirely separate tracks. Each letter runs its own response clock (typically 15 working days per the Regulatory Procedures Manual norm, discussed in the pillar), and each requires a separate remediation plan addressing that center's specific regulatory framework — CGMP for the drug side, QMSR for the device side. A compliance team tracking only one center's correspondence risks missing that a second, entirely independent enforcement track is running in parallel against the same corporate parent.
Why the numbering format doesn't tell you the center
As covered in the companion spoke on identification-block numbering, a letter's MARCS-CMS number, WL-prefixed case number, or plain CMS reference does not reliably indicate which of the six centers issued it. The center is named explicitly in the letter body — typically in the letterhead or the closing signature block — and that statement, not the number format, is the authoritative source for jurisdiction. This is a deliberate design feature worth internalizing: FDA's numbering conventions track case management history and system migrations over time, not organizational structure, so they were never built to double as a center-identification shorthand.
How escalation paths differ by center
Beyond the citation substance, the practical escalation path also differs by center. CDER and CDRH cases have well-documented paths to consent decrees and, in extreme cases, injunctions — the Pharmasol Corporation trajectory from a 2019 Warning Letter to a December 2023 consent decree is a documented CDER example. CTP's escalation path for manufacturer violations runs through the Tobacco Control Act's separate enforcement framework, distinct from the FD&C Act mechanisms the other centers rely on. A compliance team building an escalation risk model for one center's letter should not assume the same timeline or mechanism applies if a second center issues a separate letter against the same company.
What this means for a compliance program spanning multiple product types
- Map every regulated product line to its issuing center before an inspection, not after a letter arrives. Knowing in advance which center has jurisdiction over each product speeds the response and avoids confusion about which regulatory framework (CGMP, QMSR, FSVP, Tobacco Control Act) actually applies.
- Track multi-center exposure as multiple independent matters, not one. A drug-and-device company facing simultaneous CDER and CDRH letters is managing two separate response clocks and two separate remediation frameworks, not one combined matter.
- Don't infer the center from the case number format. Read the letter body for the center's explicit statement of jurisdiction.
- Escalation paths are center-specific. A CDER consent-decree timeline is not a reliable predictor of how a CTP or CVM matter might escalate; each center's enforcement ladder should be assessed on its own terms.
Related reading
- The Anatomy of an FDA Warning Letter — the pillar this spoke expands on.
- FDA Enforcement by Industry — the Cluster 4 pillar, with full center-by-industry detail.
- What Do the Numbers Mean? Decoding FDA Warning Letter ID Formats — the companion spoke on numbering conventions.
Sources
- Argus HQ, Genzyme Ireland Limited FDA Warning Letter CBER 26-728681.
- Argus HQ, Is FDA's new device quality rule a compliance reset? The first warning letters say no.
- FDA, About Warning and Close-Out Letters.
Argus HQ is informational only. Summaries are AI-assisted and may contain errors, misclassifications, or omissions. The underlying FDA Warning Letters are public records; always verify against the original source before regulatory decisions. Not legal, financial, or medical advice.